Collaboration between the Heartburn Center of California, BASS Medical Group and Torax Inc.
Walnut Creek, CA, September 11, 2018: The Heartburn Center of California is proud to announce that it has negotiated a flat rate for the LINX procedure treating eligible patients suffering from Gastroesophageal Reflux Disease (GERD). LINX is a simple, FDA approved, minimally invasive solution alternative ...
Read More
Group Pushes for FDA Warnings on Acid Reflux Medications
By Denise Dador
Tuesday, May 02, 2017 11:02PM
LOS ANGELES (KABC) -- A group in Southern California said many people suffering from acid reflux are unaware it can cause cancer, and those who do know may believe over-the-counter heartburn medications reduce their risk of developing cancer.
But the Esophageal Cancer Action Network said the medications don't protect against cancer or Barr...
Read More
HCSC Establishes Positive Coverage Policy for Torax Medical’s LINX Procedure to Treat Gastroesophageal Reflux Disease
09:00 ET from Torax Medical, Inc.
ST. PAUL, Minn., April 7, 2016 /PRNewswire/ -- Torax Medical, Inc., a leader in devices to treat sphincter-related diseases, including gastroesophageal reflux disease (GERD), announced today that Health Care Service Corporation (HCSC), the 4thlargest commercial health insurer in the U.S., has issued a medical coverage policy for the LINX® Reflux Manag...
Read More
American Medical Association Creates New Category 1 Code for Torax Medical’s LINX Procedure to Treat Gastroesophageal Reflux Disease
November 18, 2015 05:00 AM Eastern Standard Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical, Inc., a leader in therapeutic interventions for sphincter-related diseases, including gastroesophageal reflux disease (GERD), announced today the American Medical Association (AMA) has created a new Category 1 Current Procedural Terminology (CPT®) Code for esophageal sphincter augmentation using ...
Read More
Study: Long-Term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux
Abstract
Background & Aims
Based on results from year 2 of a 5-year trial, in 2012 the US Food and Drug Administration approved the use of a magnetic device to augment lower esophageal sphincter function in patients with gastroesophageal reflux disease (GERD). We report the final results of 5 years of follow-up evaluation of patients who received this device.
Methods
We performed a prosp...
Read More
New 5-Year Results of a Landmark Study Confirm LINX Procedure as a Beneficial Treatment for Gastro-esophageal Reflux Disease
Study authors conclude LINX should be a first line therapy option for GERD sufferers
PR Newswire, St. Paul, Minn. (September 14, 2015)
Torax Medical announced completion of a landmark study confirming the long-term results of the LINX® Reflux Management System in controlling reflux-related symptoms and eliminating dependence on acid suppression medications called proton pump inhibitors (PPIs). F...
Read More
New Study Demonstrates LINX® Safety and Efficacy Rivals Laparoscopic Nissen Fundoplication
Study authors conclude LINX is as effective as Nissen in controlling reflux with less side effects
July 27, 2015 05:00 AM Eastern Daylight Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical, Inc. announced today the release of new data from the University of Southern California, Keck Medical Center, a leading institution in the diagnosis and treatment of gastro-esophageal reflux disease (GERD)...
Read More
Torax Medical Announces FDA Approval of a New LINX® Device Compatible with 1.5 Tesla Magnetic Resonance Imaging (MRI) Systems
New LINX Device expands patients’ diagnostic imaging options after treatment
June 23, 2015 05:00 AM Eastern Daylight Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved a next generation LINX® Reflux Management System that is MR conditional in magnetic resonance imaging (MRI) systems up to 1.5 Tesla (...
Read More
Final Results of a Landmark 5-Year Clinical Trial for LINX®, a Revolutionary Solution for GERD, to Be Presented at the Upcoming Digestive Diseases Week Meeting
May 12, 2015 05:30 AM Eastern Daylight Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical is pleased to announce the 5-year results from a landmark clinical trial of LINX®, a revolutionary solution for GERD, will be presented at the upcoming Digestive Diseases Week (DDW) being held in Washington, DC from May 16th - 20th.
Dr. Robert Ganz, MD, FASGE, Chief of Gastroenterology, Abbott-North...
Read More
Multi Institutional Outcomes Using Magnetic Sphincter Augmentation Versus Nissen Fundoplication for Chronic Gastroesophageal Reflux Disease.
Press Release from a Poster presented at Sages 2015 (S034)
MD1,Jessica L Reynolds, MD2, John C Lipham, MD2, Joerg Zehetner, MD2, Nikolai A Bildzukewicz, MD2, Paul A Taiganides, MD3, Ralph W Aye, MD1, Alexander S Farivar, MD1, Brian E Louie, MD, MPH1.1Swedish Cancer Institute and Medical Center, 2University of Southern California,3Knox Community Hospital
Background: Historically, surgical int...
Read More